Trial Profile
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607-QIV(Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Children Aged 6~35 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2022
Price :
$35
*
At a glance
- Drugs NBP 607 QIV (Primary) ; NBP 607
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors SK Chemicals
- 31 Oct 2017 Status changed from recruiting to completed.
- 18 Jan 2017 New trial record